<!DOCTYPE html>
<html class="no-js" lang="en"  dir="ltr">
<head>
    <title>NASA SBIR 2020-I Solicitation |  H8.01-6461
        -  Biopharmaceutical Uniform Crystallization Test Bed | Proposal Summary </title>
    <meta charset="utf-8" />
</head>

<style>
    html,body {

        font-family: 'Source Sans Pro', Sans-Serif;
        color:#333;
    }
    @page {
        margin-left: 10pt;
        margin-right: 10pt;
        margin-top: 20pt;
        margin-bottom: 20pt;
    }
    .h1 {
        font-family: 'Source Sans Pro Bold', Sans-Serif;
        font-size: 18pt;
    }
    .h2 {
        font-family: 'Source Sans Pro Bold', Sans-Serif;
        font-size: 14pt;
    }
    .h4 {
        font-family: 'Source Sans Pro Bold', Sans-Serif;
        font-size: 8pt;
    }
    .divSourceSelection {
        display: table;
        width: 100%;
    }
    .divSourceSelection span {
        color: #f00;
    }
    .divTable {
        border: 1px #999 solid;
        display: table;
        width: 100%;
        padding: 10px 15px;
        margin: 15px 0px;
        font-family: 'Source Sans Pro', sans-serif;
        font-weight: 500;
        font-size: 18px;
    }
    .divTableRow {
        display: table-row;
    }
    .divTableRow .divTableCell .qtnLabel {
        font-weight: 600;
    }
    .divTableRow .divTableCell p {
        padding-top: 12px;
    }
    .divTableRow .qtnLabel {
        width: 85%;
        font-weight: 500;
        font-size: 14px;
    }
    .divTableRow .investorQtnLabel {
        width: 45%;
        font-weight: 500;
        font-size: 14px;
    }
    .divTableRow .odc-qtnLabel {
        font-size: 14px;
        width: 30%;
    }
    .divTableRow .odc-qtnAnswer {
        color: #3a3a3a;
        width: 31%;
        font-weight: 600;
        font-size: 14px;
    }
    .divTableCell {
        border: none;
        display: table-cell;
        padding: 12px 0px;
        font-size: 14px;
    }
    .divTableHead {
        text-align: center;
        border: none;
        display: table-cell;
        color: #3a3a3a;
        font-weight: 600;
    }
    .divTableBody {
        display: table-row-group;
    }
    .footerMsg {
        font-size: 10pt;
    }
    .qtnLabel {
        font-size: 14px;
        font-family: 'Source Sans Pro', Sans-Serif;
        font-weight: 500;
    }
    .qtnAnswer,  .col-20 {
        font-size: 14px;
        font-weight: 600;
        font-family: 'Source Sans Pro', Sans-Serif;
    }
    .solicitationDiv {
        text-align: right;
        float: right;
    }
    .headerDiv {
        text-align: center;
        padding-top: 10pt;
        padding-bottom: 5pt;
    }
    .header-title {
        margin: 0px;
        margin-top: 15px;
        background-color: #efefef;
        border: 1px solid #b6b6b6;
        padding: 9px;
        font-size: 15px;
    }
    .table-wrapper {
        width: 100%;
        display: inline-block;
        border-top: 0px;
    }
    .table-wrapper .table-row {
        border-bottom: 1px solid #b6b6b6;
        /* display: inline; */
        height: 15px;
        padding: 12px 20px;
    }
    .table-wrapper .table-row .cell-left {
        float: left;
        width: 30%;
        font-size: 14px;
    }
    .table-wrapper .table-row .cell-right {
        float: right;
        width: 70%;
        font-size: 14px;
        color: #5f5b58;
        font-weight: 600;
    }
    .table-wrapper .table-row:last-child {
        border-bottom: 0px;
    }
    .table-wrapper _table {
        width: 100%;
        border: 1px solid #b6b6b6;
    }
    .table-wrapper _table th_header {
        padding: 12px 9px;
        text-align: center;
        color: #999;
        font-weight: 600;
    }
    .table-wrapper _table th_header_title {
        text-align: center;
        padding: 5px 0px;
        color: #999;
    }
    .table-wrapper _table td_data {
        padding: 12px 9px;
        text-align: center;
        color: #484848;
        font-weight: 600;
    }
    .col-85{
        width:85%;
    }
    .col-30{
        width:30%;
        float:left;
    }

    .col-50 {
        width: 50%;
        float: left;
    }
    .col-70{
        width: 60%;
        float:left;
    }
    .col-20{
        width: 20%;
    }
    .col-15{
        width: 15%;
    }
    .totalCost{
        border: 1px solid #b6b6b6;
        padding: 4px 8px;
        width: 400px;
    }
    .summary-qtnLabel{
        width: 50%;
    }
    td.review_data {
        font-weight: 200;
    }
    .investorQtnLabel {
        width: 30%
    }
</style>

<body>
<div class="divSourceSelection">
    <div class="divTableBody">
        <div class="divTableRow">
            <div class="divTableHead">
            </div>
        </div>
    </div>
</div>
<div class="solicitationDiv"><h4>NASA SBIR 2020-I Solicitation</h4></div>
<div class="headerDiv"><h2>Proposal Summary</h2></div>
<HR noShade SIZE="3">
<div class="divTable">
    <div class="divTableBody">
            <div class="divTableRow">
                <div class="divTableCell col-20"><strong>PROPOSAL NUMBER:</strong></div>
                <div class="divTableCell">&nbsp;20-1-&nbsp;<strong>H8.01-6461</strong></div>
            </div>
        <div class="divTableRow">
            <div class="divTableCell col-20"><strong>SUBTOPIC TITLE:</strong></div>
            <div class="divTableCell">&nbsp;Utilization of the International Space Station (ISS) to Foster Commercial Development of Low-Earth Orbit (LEO)</div>
        </div>
        <div class="divTableRow">
            <div class="divTableCell col-20"><strong>PROPOSAL TITLE:</strong></div>
            <div class="divTableCell">&nbsp;Biopharmaceutical Uniform Crystallization Test Bed</div>
        </div>
    </div>
</div>



<B>SMALL BUSINESS CONCERN</B> (Firm Name, Mail Address, City/State/Zip, Phone)<BR>
        Techshot, Inc. <BR>
        7200 Highway 150 <BR>
        Greenville, IN 47124 <BR>
        (812) 923-9591

<h3 class="header-title">
    <strong><span>Principal Investigator</span></strong> (Name, E-mail, Mail Address, City/State/Zip, Phone)
</h3>
<div class="table-wrapper">
    <div class="table-row">
        <div class="cell-left">Name:</div>
        <div class="cell-right">
            
            Rachel Ormsby
        
        </div>
    </div>

    <div class="table-row">
        <div class="cell-left">E-mail:</div>
        <div class="cell-right">rormsby@techshot.com</div>
    </div>
    <div class="table-row">
        <div class="cell-left">Address:</div>
        <div class="cell-right">
            <span class="street">7200 Highway 150</span>
            <span class="street">Greenville,
                     IN
                47124
         - 9515</span>
        </div>
    </div>
    <div class="table-row">
        <div class="cell-left">Phone:</div>
        <div class="cell-right">(812) 728-8122</div>
    </div>
</div>

<h3 class="header-title">
    <strong><span>Business Official</span></strong> (Name, E-mail, Mail Address, City/State/Zip, Phone)
</h3>
<div class="table-wrapper">
    <div class="table-row">
        <div class="cell-left">Name:</div>
        <div class="cell-right">
            Ms.
            Juanita Melton
        
        </div>
    </div>
    <div class="table-row">
        <div class="cell-left">E-mail:</div>
        <div class="cell-right">jmelton@techshot.com</div>
    </div>
    <div class="table-row">
        <div class="cell-left">Address:</div>
        <div class="cell-right">
            <span class="street">7200 Highway 150</span>
            <span class="street">Greenville,
                     IN
                47124
         - 9515</span>
        </div>
    </div>
    <div class="table-row">
        <div class="cell-left">Phone:</div>
        <div class="cell-right">(812) 728-8135</div>
    </div>
</div>

<div class="divTable">
    <div class="divTableBody">
        <div class="divTableRow">
            <div class="divTableCell">
                <span class="qtnLabel"><strong>Estimated Technology Readiness Level (TRL) : </strong></span>
                <br>Begin:
                3
                <br>End:
            6
            </div>
        </div>
        <div class="divTableRow">
            <div class="divTableCell">
                <span class="qtnLabel"><strong>Technical Abstract</strong></span> (Limit 2000 characters,
                approximately
                200 words)
                <BR>
        <p style="margin: 0in 0in 8pt;"><font color="#000000">Pharmaceuticals in general, and biopharmaceuticals specifically, are often best formulated as microscopic crystals.</font><font color="#000000">&nbsp; </font><font color="#000000">The crystalline state is most stable, allows a high-concentration, low-viscosity parenteral formulation, and facilitates alternate routes of administration. There is a requirement that the crystals be small, a few micrometers or less, and uniform, the same size within a few per cent.</font><font color="#000000">&nbsp; </font><font color="#000000">The problem: most recombinant protein biopharmaceuticals do not crystallize uniformly.</font><font color="#000000">&nbsp; </font><font color="#000000">A solution to this problem has been discovered in on-orbit crystallization experiments, which produced very uniform sized crystals. Manufacturers are creating demand for on-orbit testing of uniform crystallization protocols, but suitable hardware and ISS research opportunities are inadequate.</font><font color="#000000">&nbsp; </font><font color="#000000">Techshot proposes a business plan in which cost and time saving versatile flight hardware and flexible flight opportunities are made openly available to corporate and institutional users seeking improvements or refinements in product purification, formulation and/or delivery.</font><font color="#000000">&nbsp; </font><font color="#000000">Hardware and flight plans on ISS will be offered in which factorial and/or real-time photography experiments can be performed on the basis of Techshot&rsquo;s regular ISS access and versatile hardware fleet.</font><font color="#000000">&nbsp; </font><font color="#000000">In Phase I research Techshot will (1) adapt up to four different existing hardware modules for this specific application, (2) test these modules in model protein crystallization experiments in the laboratory, and (3) perform mathematical modeling for a ground-based crystallization reactor with adjustable parameters for approximating the relevant low-gravity physics.</font><font color="#000000">&nbsp; </font><font color="#000000">In Phase II research Techshot will prepare the hardware modules for flight readiness, prepare an aggressive ISS use plan, and construct and operate an optimizable ground-based reactor.</font><font color="#000000">&nbsp; </font><font color="#000000">The intended outcome is a business paradigm for hastening the availability of stable biopharmaceuticals with favorable options for delivery.</font></p>

            </div>
        </div>
        <div class="divTableRow">
            <div class="divTableCell">
                <span class="qtnLabel"><strong>Potential NASA Applications</strong></span> (Limit 1500
                characters, approximately 150 words)
                <BR>
        <p style="margin: 0in 0in 8pt;"><font>NASA has solicited research topics in this area of pharmaceutical production on spacecraft making deep space voyages to solve problems of availability and stowage.</font><font>&nbsp; </font><font>Such projects include short-cut production of biopharmaceuticals by stored microbial cells but also need to include short-cut purification schemes.</font><font>&nbsp;&nbsp; </font><font>A crystallization plan, Techshot&rsquo;s proposed innovation, could eliminate several (chromatography, extraction, etc.) downstream steps toward such on-orbit formulation, although non-NASA commercialization is the project&rsquo;s primary goal. </font></p>

            </div>
        </div>
        <div class="divTableRow">
            <div class="divTableCell">
                <span class="qtnLabel"><strong>Potential Non-NASA Applications</strong></span> (Limit 1500
                characters, approximately 150 words)
                <BR>
        <p><font color="#000000">Success in producing a crystalline product will save big due to longer ambient stability, lower delivery volume and novel routes of administration of their product, whether it is an approved pharmaceutical or an emerging therapeutic.</font><font color="#000000">&nbsp;</font><font color="#000000">Techshot intends to offer crystallization research capabilities on the ISS and in labs to companies seeking opportunities in the crystalline biopharmaceutical field. </font></p>

            </div>
        </div>
        <div class="divTableRow">
            <div class="divTableCell">
                <span class="qtnLabel"><strong>Duration:</strong>
                6
            </div>
        </div>
    </div>
</div>


<HR noShade SIZE="3">
<span class="footerMsg">Form Generated on 06/29/2020 20:59:04</span>

</BODY>
</HTML>
